Clinical trials on Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

  • CT-EU-00119224

    Testing povetacicept for patients with lupus nephritis, IgA nephropathy, membranous nephropathy, or ANCA-associated vasculitis

    The clinical study focuses on patients with autoimmune kidney diseases, including immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. The study aims to determine if povetacicept (ALPN-303) is safe and potentially beneficial in treating these diseases.

    During the study, participants will receive povetacicept approximately every 4 weeks for 6 months. There is also the possibility of participating in a 6-month treatment extension period and an optional 52-week treatment extension period. The study includes several dose levels of povetacicept, and participants will be assigned to either an 80mg or 240mg dose of the drug, administered by subcutaneous injection.

    The primary goal of the study is to assess the safety of povetacicept by monitoring the type, incidence, severity, and seriousness of any adverse events during and after the treatment period.

    • povetacicept